Compounds for treatment of cancer
AssigneesOncternal Therapeutics, Inc., University of Tennessee Research Foundation
InventorsWei Li, Min Xiao, James Dalton, Sunjoo Ahn, Duane D Miller, Jin Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
Claims11
A method of treating cervical cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound having the structure of formula XI:
- wherein
- X is a bond;
- Q is NH;
- A is substituted or unsubstituted single-, fused- or multiple-ring, (hetero)cyclic ring systems;
- substituted or unsubstituted, saturated or unsaturated N-heterocycles;
- substituted or unsubstituted, saturated or unsaturated S-heterocycles;
- substituted or unsubstituted, saturated or unsaturated O-heterocycles;
- substituted or unsubstituted, unsaturated cyclic hydrocarbons;
- or substituted or unsubstituted or saturated or unsaturated mixed heterocycles;
- wherein the A ring is optionally substituted by 1-5 substituents independently selected from O-alkyl, O-haloalkyl, F, Cl, Br, I, CN, —CH2CN, NH2, hydroxyl, —OC(O)CF3, C1-C5 linear or branched alkyl, haloalkyl, alkylamino, aminoalkyl, —OCH2Ph, —NHCO-alkyl, COOH, —C(OPh, C(O)O-alkyl, C(O)H, —C(O)NH2 or NO2,
- or an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, N-oxide, or combinations thereof.
A method of treating cervical cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound having the structure of formula XI:
- wherein
- X is a NH;
- Q is NH or S;
- A is substituted or unsubstituted single-, fused- or multiple-ring (hetero)cyclic ring systems;
- substituted or unsubstituted, saturated or unsaturated N-heterocycles;
- substituted or unsubstituted, saturated or unsaturated S-heterocycles;
- substituted or unsubstituted, saturated or unsaturated O-heterocycles;
- substituted or unsubstituted, saturated or unsaturated cyclic hydrocarbons;
- or substituted or unsubstituted or saturated or unsaturated mixed heterocycles;
- wherein the A ring is optionally substituted by 1-5 substituents which are independently O-alkyl, O-haloalkyl, F, Cl, Br, I, CN, —CH2CN, NH2, hydroxyl, —(CH2)iNHCH3, —(CH2)iNH2, —(CH2)iN(CH3)2, —OC(O)CF3, C1-C5 linear or branched alkyl, haloalkyl, alkylamino, aminoalkyl, —OCH2Ph, —NHCO-alkyl, COOH, —C(O)Ph, C(O)O-alkyl, C(O)H, —C(O)NH2 or NO2;
- and
- i is an integer between 0-5, or an isomer, pharmaceutically acceptable salt, pharmaceutical product, tautomer, hydrate, N-oxide, or combinations thereof.
Dependencies are inferred from the claim text.